Belyntic GmbH is one of this year's winners of the Innovation Award Berlin-Brandenburg. With this award, the jury honors the start-up, located in the Science and Technology Park Berlin-Adlershof, for its "unique technology for research, development, and production of peptide therapeutics". Belyntic's technology Peptide Easy Clean (PEC) is based on a chemical linker molecule for the manufacturing of peptides (short proteins).
The PEC technology enables significantly higher reliability in drug discovery. Thanks to solvent savings of more than 75%, the process developed by Belyntic is also economically and ecologically attractive in drug production. Moreover, PEC allows the production of complex and thus even more effective peptide therapeutics - for example to combat cancer, diabetes, or infectious diseases such as COVID-19. Belyntic is already involved in the development of a vaccine against SARS-CoV-2; the company plans to drive forward its own development projects of therapeutic peptide vaccines from 2021.
"It is a great honor for us to be the winner of this prestigious innovation award. With our technology, we want to enable a healthier life through even more effective drugs. That is our vision. We are pleased about the growing interest in it", says Belyntic co-founder Andreas Regnery. "Two years ago we founded our company. Since then, we have continuously developed our technology and product portfolio to get closer to our vision. Winning the Innovation Award shows us that we are on the right track," says Dominik Sarma, who is also one of the four founders of the company.
The Berlin-Brandenburg Innovation Award has been presented by the Senate Department for Economics, Energy and Public Enterprises since 1984 and since 1992 jointly with the Brandenburg Ministry of Economics (now the Ministry of Economic Affairs, Labor and Energy). The prize is endowed with 10,000 euros each and is awarded annually to a maximum of five applicants. Since 1984, more than 4,000 applications have been submitted and more than 160 prize winners have been awarded. The nominations of the finalists and prize winners are made by an independent jury of experts. With the involvement of commercial enterprises and other institutions as private partners, the prize was and is also a public-private prize and thus a joint project.
About the Belyntic GmbH:
Belyntic GmbH, founded in 2018, is a Chemistry-for-Healthcare company. Belyntic offers solutions for the development and production of peptide drugs based on their patent-pending PEC technology. The company's headquarters are located at the Federal Institute for Materials Research and Testing (BAM), Richard-Willstätter-Str. 11, 12489 Berlin, Germany.
For further information, please visit https://belyntic.com or contact Dominik Sarma, co-founder, and co-managing director at 030 8104-1113 or by email at firstname.lastname@example.org.